Endo to buy generic drugmaker Qualitest for $1.2 billion

BANGALORE (Reuters) – Endo Pharmaceuticals Holdings Inc agreed to buy Qualitest Pharmaceuticals, a privately held generics company, for about $1.2 billion as it prepares to fill the expected revenue gap when the patent on its key pain drug expires.

Leave a Reply